Articles

Although cardiovascular disease is largely avoidable through lifestyle modifications, it remains the nation’s number one cause of death. While annual wellness exams offer physicians the chance to...

FDA Clears Lutonix 035 Drug Coated Balloon C.R. Bard Inc.

C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approval of the Lutonix 035 drug-coated balloon (DCB) catheter for percutaneous transluminal angioplasty (PTA) after pre-...

October 10, 2014—Mitralign Inc. reported on the successful use of its technology to perform a percutaneous repair on a patient with tricuspid regurgitation (TR). Prof. Dr. med. J. Schofer of the...

October 10, 2014 — Despite ongoing commercial challenges in 2013, the global medtech industry’s financial performance held steady at the relatively low levels of growth that have...

The swift migration to cloud computing and data recovery services shows no signs of slowing, with half of organizations reporting they expect to boost their cloud services budgets over the next 18...

October 8, 2014 — New updates to the Society for Cardiovascular Angiography and Interventions (SCAI) appropriate use criteria (AUC) calculator tool will help healthcare providers in making...

Clinical trial results by Recover Right revealed a survival rate of 73 percent in the total patient population. Recover Right was an FDA-approved, prospective, multicenter, single arm study...

October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioresorbable vascular scaffold (BVS) is more cost effective and offers a...

More than 40 percent of Americans aged 40 and older have experienced one or more of the most common symptoms[1] of peripheral arterial disease (PAD).

Ekos for PE

Acute intermediate-risk pulmonary emboli (PE) in normotensive patients with right ventricle dysfunction present the clinician with a quandary. With a 3 percent mortality rate[1] — just shy of the...